Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.

Erik VoetsMarc ParadéDavid Lutje HulsikSanne SpijkersWout JanssenJoost RensInge Reinieren-BeerenGilbert van den TillaartSander van DuijnhovenLilian DriessenMaurice HabrakenPeter van ZandvoortJoost KreijtzPaul VinkAndrea van ElsasHans van Eenennaam

Published in: Journal for immunotherapy of cancer (2019)

Blocking the SIRPα-CD47 interaction via SIRPα, while similarly efficacious in vitro, differentiates ADU-1805 from CD47-targeting agents with respect to safety and absence of inhibition of T-cell activation. The data presented herein support further advancement of ADU-1805 towards clinical development.

Keyphrases

immune response
nk cells
machine learning
cancer therapy
artificial intelligence